Use of daptomycin to treat drug-resistant Gram-positive bone and joint infections

Current Medical Research and Opinion

Volumn 21, Issue 12, 2005, Pages 1923-1926

  Finney, Michael S ^a   Crank, Christopher W ^b   Segreti, John ^b  

^a Fountain Valley Regional Hospital and Medical Center   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Daptomycin; Osteomyelitis; Septic arthritis

Indexed keywords

AMPICILLIN; CREATINE KINASE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; LINEZOLID; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL ARTHRITIS; BACTERIUM ISOLATION; BONE INFECTION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; ENTEROCOCCUS; FEMALE; GRAM POSITIVE BACTERIUM; HUMAN; INFECTION SENSITIVITY; INFECTIOUS ARTHRITIS; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAUSEA; OSTEOMYELITIS; RELAPSE; RETROSPECTIVE STUDY; SAMPLE SIZE; STREPTOCOCCUS INFECTION; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; BONE DISEASES; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; JOINT DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 29144460270     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X74961     Document Type: Article

References (17)

1. NNIS System. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control 1999;27:520-32
2. Charlebois ED, Perdreau-Remington F, Kreiswirth B, et al. Origins of community strains of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2004;39:47-54
3. Centers for Disease Control. Staphylococcus aureus resistant to vancomycin - United States, 2002. Morb Mortal Wkly Rep 2002;51:565-7
4. Lew DP, Waldvogel SA. Osteomyelitis. N Engl J Med 1997;336:999-1007
5. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990;34:1227-31
6. Tice AD, Hoaglund PA, Shoultz DA. Risk factors and treatment outcomes in osteomyelitis. J Antimicrob Chemother 2003;51:1261-8
7. Rayner CR, Baddour LM, Birmingham MC, et al. Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection 2004;32:8-14
8. Rao N, Ziran BH, Hall RA, et al. Successful treatment of chronic bone and joint infections with oral linezolid. Clin Orthop 2004;67-71
9. Liao CH, Tseng SP, Fang CT, et al. First linezolid- and vancomycin-resistant Enterococcus faecium strain in Taiwan. J Antimicrob Chemother 2005;55:598-9
10. Peeters MJ, Sarria JC. Clinical characteristics of linezolid-resistant Staphylococcus aureus infections. Am J Med Sci 2005;330:102-4
11. Bernstein WB, Trotta RF, Rector JT, et al. Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann Pharmacother 2003;37:517-20
12. MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 2003;51(Suppl 2):ii17-25
13. Arbeit RD, Maki D, Tally FP, et al., Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2004;38:1673-81
14. Tally FP, DeBruin MF. Development of daptomycin for Gram-positive infections. J Antimicrob Chemother 2000;46:523-6
15. Thorne GM. Daptomycin: a novel lipopeptide antibiotic. Clin Microbiol Newsl 2002;24:33-40
16. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991;115:674-80
17. Silverman JA, Oliver N, Andrew T, et al. Resistance studies with daptomycin. Antimicrob Agents Chemother 2001;45:1799-802